Quarrion’s Syndrome (Hypersensitivity Pneumonitis)
Overview
Quarrion’s syndrome, more commonly known as hypersensitivity pneumonitis (HP), is an immune‑mediated inflammatory lung disease that occurs after repeated inhalation of a wide variety of airborne antigens (often organic particles). The immune system reacts as if the inhaled substances were harmful, leading to inflammation of the alveoli and small airways. Over time, chronic exposure can cause irreversible fibrosis.
- Who it affects: Anyone can develop HP, but it is most common in adults 30‑60 years old who work or live in environments with high exposure to mold, bird proteins, farm dust, chemicals, or certain occupational aerosols.
- Prevalence: Exact global numbers are difficult to determine because HP is under‑diagnosed. In the United States, an estimated CDC study reported 1–2 cases per 100,000 people annually, with higher rates (up to 12 per 100,000) among agricultural workers and bird‑keeping enthusiasts.1
- Gender: Slight predominance in women when the trigger is bird exposure (e.g., pigeon breeders) and in men when the trigger is farming or woodwork.
Because HP mimics other respiratory illnesses (asthma, COPD, interstitial lung disease), a high index of suspicion and a detailed exposure history are essential for diagnosis.
Symptoms
Symptoms can be divided into three patterns based on exposure duration: acute, sub‑acute, and chronic.
Acute HP (hours to days after exposure)
- Fever & chills – often sudden, low‑grade (≤38.5 °C).
- Dry cough – non‑productive, may be hacking.
- Shortness of breath – rapid onset, especially during physical activity.
- Chest tightness or pain – pleuritic quality.
- Malaise, fatigue, muscle aches.
- Wheezing – can be mistaken for asthma.
Sub‑acute HP (weeks to months of intermittent exposure)
- Persistent dry cough.
- Gradual dyspnea on exertion.
- Low‑grade fever that may wax and wane.
- Weight loss and decreased appetite.
- Generalized fatigue.
Chronic HP (months to years of ongoing exposure)
- Progressive shortness of breath, even at rest.
- Chronic, dry or minimally productive cough.
- Clubbing of the fingertips (in advanced disease).
- Exercise intolerance.
- Weight loss, muscle wasting.
- Signs of right‑sided heart failure (cor pulmonale) in severe cases.
Symptoms often improve or disappear when the offending antigen is avoided, only to recur with re‑exposure.
Causes and Risk Factors
HP is not caused by a single pathogen but by an exaggerated immune response to inhaled antigens. These antigens fall into two broad categories:
Organic Antigens (most common)
- Bird proteins: feather, droppings, or dander from pigeons, parrots, chickens (often called “bird‑fancier’s lung”).
- Mold spores: Aspergillus, Penicillium, Cladosporium (known as “farmer’s lung”).
- Thermophilic actinomycetes: bacteria in hay, compost, or wheat (also “farmer’s lung”).
- Mycobacteria and fungi in indoor water‑damaged buildings.
- Other: milk dust, cheese ripening environments, and certain animal farms.
Inorganic/Non‑biologic Antigens (less common)
- Isocyanates (found in spray paints, foams).
- Metal dusts (e.g., nickel, beryllium).
- Silica particles, wood dust.
Risk Factors
- Occupational exposure: farming, poultry processing, woodworking, textile manufacturing, metalworking, and indoor–environment remediation.
- Hobbies: bird‑keeping, mushroom cultivation, mushroom foraging, indoor gardening with heavy compost use.
- Genetic susceptibility: Certain HLA alleles (e.g., HLA‑DRB1*13) have been linked with higher risk of HP.
- Smoking: While smoking may blunt acute symptoms, it increases the likelihood of progression to chronic fibrosis.
- Pre‑existing lung disease: COPD or asthma can complicate presentation and outcomes.
Diagnosis
Diagnosing HP requires a combination of clinical history, imaging, laboratory tests, and sometimes lung biopsy. No single test is definitive.
1. Detailed Exposure History
Identify occupational or hobby‑related inhalant exposures. A structured questionnaire (e.g., the HP Exposure Questionnaire) is often used.
2. Physical Examination
May reveal inspiratory crackles (fine “Velcro” sounds), wheezing, or, in chronic disease, clubbing.
3. Laboratory Tests
- Complete blood count (CBC): May show mild leukocytosis.
- Serum precipitating antibodies: Detection of specific IgG against the suspected antigen (positive in 50–70 % of cases). However, a positive test alone is insufficient for diagnosis.
- Bronchoalveolar lavage (BAL): Fluid typically shows lymphocytosis (>20 % lymphocytes). The CD4/CD8 ratio can be helpful (<1 in many HP cases).
4. Pulmonary Function Tests (PFTs)
- Restrictive pattern: Decreased forced vital capacity (FVC).
- Reduced diffusion capacity (DLCO): Often the earliest functional abnormality.
- Obstructive component: May be present if airway hyperresponsiveness co‑exists.
5. Imaging
- Chest X‑ray: May be normal in early disease; later shows diffuse reticulonodular infiltrates.
- High‑resolution CT (HRCT) scan – gold standard imaging: Findings vary with stage:
- Acute: ground‑glass opacities, centrilobular nodules.
- Sub‑acute: mosaic attenuation, air‑trapping, vague fibrosis.
- Chronic: honeycombing, traction bronchiectasis, dense fibrosis, especially in upper lobes.
6. Lung Biopsy (when diagnosis remains uncertain)
Transbronchial cryobiopsy or surgical (video‑assisted thoracoscopic surgery) biopsy may reveal an interstitial infiltrate of lymphocytes, poorly formed granulomas, and fibrosis.
Diagnostic Criteria (adapted from ATS/ERS 2020 guideline)
- Identification of a plausible inciting antigen.
- Typical HRCT pattern.
- Supportive BAL or histopathology.
- Improvement after antigen avoidance or corticosteroid therapy.
Treatment Options
Therapy focuses on eliminating exposure, controlling inflammation, and addressing complications.
1. Antigen Avoidance
- Remove the source: relocate pets, improve ventilation, wear protective equipment, or change job duties.
- Environmental remediation: professional mold remediation, air filtration (HEPA filters) and humidity control (<30 % relative humidity).
2. Pharmacologic Therapy
- Corticosteroids: First‑line for acute and sub‑acute HP.
- Prednisone 0.5–1 mg/kg/day for 2–4 weeks, then a gradual taper over 3–6 months.
- Improvement in symptoms and PFTs is often seen within 2–4 weeks.
- Immunosuppressive agents (for steroid‑dependent or chronic disease):
- Azathioprine 1.5–2 mg/kg/day.
- Mycophenolate mofetil 1–1.5 g twice daily.
- These agents may help stabilize lung function and reduce steroid side‑effects.
- Antifibrotic drugs (in progressive fibrotic HP): Nintedanib (approved for idiopathic pulmonary fibrosis) has shown benefit in slowing FVC decline in chronic HP (INBUILD trial, 2020).2
3. Supportive Measures
- Supplemental oxygen for resting hypoxemia (SpO₂ < 88 %).
- Pulmonary rehabilitation: exercise training, breathing techniques, and education to improve quality of life.
- Vaccinations: influenza annually, pneumococcal (PCV20 or PCV15 + PPSV23) per CDC schedule.
- Smoking cessation counseling.
4. Procedural Interventions (rare)
- Therapeutic bronchoscopy to clear large airway obstruction.
- Lung transplantation for end‑stage fibrotic disease (5‑year survival ≈ 55 %).
Living with Quarrion’s Syndrome (hypersensitivity pneumonitis)
Long‑term management is individualized and requires collaboration between the patient, pulmonologist, occupational health specialist, and sometimes a psychologist.
Daily Management Tips
- Maintain a clean environment: Clean surfaces with damp cloths, avoid dry dusting, and use HEPA vacuum cleaners.
- Control indoor humidity: Keep relative humidity between 30‑50 % to deter mold growth. Use dehumidifiers in basements and bathrooms.
- Protective equipment: When exposure cannot be eliminated, wear N95/FFP2 respirators, goggles, and disposable coveralls.
- Medication adherence: Take corticosteroids or immunosuppressants exactly as prescribed; never abruptly stop steroids.
- Monitor symptoms: Keep a daily log of cough, breathlessness, and temperature; report any worsening promptly.
- Regular follow‑up: Pulmonary function testing every 3–6 months for the first year, then yearly if stable.
- Exercise wisely: Low‑impact activities (walking, stationary cycling) improve endurance without overexertion.
- Nutrition: Balanced diet rich in antioxidants (fruits, vegetables) to support immune health; maintain adequate protein to prevent muscle wasting.
- Psychosocial support: Chronic disease can cause anxiety or depression; consider counseling or support groups.
Prevention
Because HP is fundamentally an exposure‑related disease, prevention hinges on reducing inhalant contact.
- Occupational safety: Implement engineering controls (ventilation, local exhaust), administrative controls (rotating staff), and personal protective equipment (PPE) per OSHA guidelines.
- Home environment: Inspect for water damage, repair leaks immediately, and use mold‑resistant building materials.
- Hobby precautions: If you keep birds, keep cages outdoors or in well‑ventilated rooms; wear masks while cleaning droppings. For mushroom or indoor gardening, use gloves, masks, and work in a well‑ventilated area.
- Education: Awareness programs for at‑risk workers (farmers, poultry workers, hobbyists) improve early recognition and prompt avoidance.
- Vaccination: Influenza and pneumococcal vaccines reduce the risk of secondary infections that can exacerbate HP.
Complications
If untreated or if exposure continues, HP can progress to irreversible lung damage.
- Fibrotic chronic HP: Leads to permanent scarring, progressive dyspnea, and reduced lung capacity.
- Cor pulmonale: Right‑ventricular strain due to chronic hypoxia.
- Respiratory failure: May require long‑term oxygen therapy or mechanical ventilation.
- Secondary infections: Damaged lung tissue is more susceptible to bacterial pneumonia.
- Bronchogenic carcinoma: Chronic inflammation and fibrosis slightly increase cancer risk, especially in smokers.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden worsening of shortness of breath (cannot speak full sentences).
- Chest pain that is sharp, persistent, or radiates to the back or shoulder.
- Rapid heart rate (tachycardia) accompanied by dizziness or fainting.
- Bluish discoloration of lips, fingertips, or skin (cyanosis).
- Severe coughing with blood-tinged sputum.
- New onset fever > 38.5 °C (101.3 °F) with worsening respiratory symptoms.
These signs may indicate acute respiratory failure, a severe exacerbation, or a superimposed infection that needs immediate medical attention.
References
- American Lung Association. “Hypersensitivity Pneumonitis.” Accessed May 2026. lung.org.
- Richeldi L, et al. “Nintedanib for Progressive Fibrotic Interstitial Lung Diseases.” New England Journal of Medicine. 2020;383:1542‑1552. doi:10.1056/NEJMoa2026830.
- Mayo Clinic Staff. “Hypersensitivity Pneumonitis.” Mayo Clinic. Updated 2024. mayoclinic.org.
- World Health Organization. “Guidelines for the Prevention and Control of Occupational Respiratory Diseases.” WHO, 2023.
- Cleveland Clinic. “Hypersensitivity Pneumonitis (Extrinsic Allergic Alveolitis).” 2024. clevelandclinic.org.